Asset Details
Do you wish to reserve the book?
Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
Do you wish to request the book?
Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
2010
Overview
During follow-up of leukocyte counts in 20 consecutive patients (age range 29–81 years) treated with dasatinib, 9 patients (7 chronic myeloid leukemia in chronic phase, 2 Philadelphia chromosome-positive acute lymphoid leukemia in complete remission) developed lymphocytosis (>3,000/μl). Peripheral blood smears revealed a population of large granular lymphocytes. Large granular lymphocytosis (LGL) was first noted between 1 and 8 months after initiation of dasatinib, and it has persisted up to 33 months from the onset of LGL in one patient. Peak numbers of large granular lymphocytes ranged from 2,915 to 17,425/μl. The occurrence of LGL might interfere with achieving molecular response (MR, real-time quantification of major
BCR
-
ABL1
mRNA less than 50 copies/μg RNA) in our small cohort; 8 (89%) of 9 patients with LGL attained MR, while only 6 (55%) of 11 patients without LGL eventually achieved MR. With respect to the relationship between LGL and pleural effusion (PE), 3 (27%) of 11 patients without LGL developed PE, while 5 (56%) of 9 patients with LGL developed PE. Moreover, the mean peak number of LGL was 9,215/μl, which was much higher than the mean peak number (4,635/μl) of LGL in patients without PE. These results may suggest possible association of both events in our cohorts.
Publisher
Springer Japan,Springer,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Biological and medical sciences
/ Female
/ Hematologic and hematopoietic diseases
/ Humans
/ Large granular lymphocytosis
/ Leukemia, Large Granular Lymphocytic - chemically induced
/ Leukemia, Large Granular Lymphocytic - pathology
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
/ Lymphocytosis - chemically induced
/ Male
/ Medicine
/ Oncology
/ Pleural Effusion - chemically induced
/ Pleural Effusion - pathology
/ Protein Kinase Inhibitors - adverse effects
/ Pyrimidines - adverse effects
